ライフサイエンスコーパス: VAS

1 VAS for pain improved from 6.5 preoperatively to 4.2 (p<

2 VAS perception and anxiety scores did not change on firs

3 VAS was independently associated with MSNA burst frequen

4 VAS work correlates with other outcomes (VAS global, nos

5 VAS work should be considered as a potentially useful AR

6 VAS, K-L, and KOOS all significantly separated the OA an

7 ta across the two diagnostic groups (p = .01 VAS, p = .02 HDRS-17).

8 d over 1 year (PCS p = 0.02; EQ-5D p = 0.02; VAS p = 0.01; SF-6D p = 0.03), becoming similar to age-a

9 baseline first-hour cough frequency (CF(1)), VAS, and LCQ to identify low CF(24) was assessed.

10 CF(24), VAS, and LCQ are responsive outcome tools for the assess

11 total score (0.63, 0.52-0.75), and EQ-5D-3L VAS score (HR 0.75, 95% CI 0.63-0.89) and UK utility sco

12 was improvement of at least 30 mm in 2 of 4 VASs by week 24.

13 as a greater than 35% LSAS reduction and 50% VAS-Anxiety reduction.

14 , pain, and anxiety), as well as lower EQ-5D VAS and EQ-5D index scores.

15 in HRQoL, based on SNOT-22, SF-36, and EQ-5D VAS scores.

16 001) and a lower EQ-5D index value and EQ-5D VAS value (P < 0.001) compared to those with asthma only

17 onnaire and 48 (83%) had completed the EQ-5D VAS.

18 Mean satisfaction rate was 86.9 +/- 13.65 (VAS) and showed a positive correlation with willingness

19 Among them, 1 887 users reported >=7 VAS data.

20 vs 2 [IQR, 0-3] for promethazine [P = .81], VAS [0-10 scale] for nausea, 2 [IQR, 1-5] vs 2 [IQR, 1-4

21 of the 45 patients achieved and maintained a VAS score of 0 during the 3-year observation period.

22 dary efficacy end points included additional VAS items (burning/stinging, itching, foreign body sensa

23 The adherence VAS improved from 59.7 (95% CI, 54.0-65.3) to 88.6 (95%

24 P < 0.05) such that glucose-to-ileum altered VAS-rated fullness, satisfaction, and thoughts of food c

25 the overall feeling of sickness at altitude (VAS[O]; various thresholds), Acute Mountain Sickness-Cer

26 lcoxon signed-rank test z=2.24, p=0.025) and VAS (88.89% response ketamine vs 52.94% response placebo

27 d at baseline and 6 months using OHIP-14 and VAS scale in the early post-therapy period.

28 re was a significant reduction in CF(24) and VAS, and improvement in LCQ, from visits 1-3.

29 ttern of change remained for PCS, EQ-5D, and VAS (p < 0.05).

30 creased operator experience (PCS, EQ-5D, and VAS p < 0.05) were independent predictors of a greater i

31 s (difference, 32.4; 95% CI, 24.9-39.8), and VAS satisfaction (difference, 33.2; 95% CI, 25.4-41.0) s

32 orrelation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001, Spearman's rank test).

33 ere assayed and correlated with clinical and VAS information in 40 patients.

34 h a decrease of 51-60% in TPs, FIQ, HAQ, and VAS scales, and in the number of prescribed drugs, accom

35 The smallest changes in CF(24), LCQ, and VAS that subjects perceived important were 54%, 2- and 1

36 e, all patients had poor Quality of Life and VAS scores, a high number of TPs and drug prescriptions,

37 The mean ItchyQoL total score and VAS symptom score were significantly improved in the rup

38 0.47, 95% CI - 0.71 to - 0.23) subscales and VAS (SMD = - 0.79, 95% CI - 1.05 to - 0.05).

39 ng the m-ARIA, significantly higher T4SS and VAS scores were obtained when comparing severe with mode

40 ients recorded higher perception and anxiety VAS scores than patients undergoing surgery for the thir

41 ment (P=0.046 for treatment arm and baseline VAS interaction).

42 e primary end point was change from baseline VAS score in 24-hour pain averaged over days 14-18.

43 as outcomes in patients with higher baseline VAS scores were similar regardless of treatment assignme

44 No such difference was seen if baseline VAS was >/=55 (70+/-7% versus 75+/-9%; P=0.79).

45 ersus optimal medical management if baseline VAS was <55, whereas outcomes in patients with higher ba

46 Among patients with baseline VAS<55, survival on original treatment was lower for opt

47 There was a significant correlation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001,

48 there was a significant correlation between VAS-work and WPAI:AS (Rho=0.53, P<0.0001).

49 No correlations between VAS score and laboratory inflammatory markers were ident

50 ed significant negative correlations between VAS score and MR imaging bowel wall arterial phase enhan

51 The correlations between VAS, EQ-5D and LupusQoL were significant; relative good

52 A strong correlation was observed between VAS work and other VAS.

53 roup, m-YPAS positively correlated with both VAS and FLACC (P = 0.000 and 0.002, respectively).

54 nts of musical sound quality, as assessed by VAS.

55 work were found with VAS global, followed by VAS nose, eye and asthma.

56 sis; reliability ratios were used to compare VAS and UCEIS scores.

57 erformance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medicat

58 evalence of chronic disabling complications (VAS score >30 for pain/numbness/groin discomfort) at 12

59 Conclusion VAS assessment of HRQOL changes over time in response to

60 mptoms of allergic rhinitis were controlled (VAS-global <20) in approximately 60% of the days.

61 y healthy subjects with URTI completed cough VAS, Leicester Cough Questionnaire (LCQ-acute), and CF(2

62 of patients with moderate-to-severe CRSwNP (VAS > 3-10) decreased from 86.2% to 21.4% with dupilumab

63 visual analogue scale area under the curve (VAS AUC) to day 5 and the proportion of patients with mo

64 vs. first dose of doxazosin: mean difference VAS -10 mm (95% CI -18 to -2) P = 0.02, blockage -0.7 (9

65 Each user filled 4 different VAS measuring overall, nasal, ocular, and asthma symptom

66 with recovery between first and last doses: VAS 15 mm (95% CI 4-25) P = 0.009, blockage 1.1 (95% CI

67 ionnaire visual analogue scale [EQ-5D-FL, EQ-VAS], and the Functional Assessment of Cancer Therapy-Pr

68 Time to deterioration of EQ-VAS was significantly longer for enzalutamide than for p

69 groups in EQ-5D-3L visual analogue scale (EQ-VAS) or utility scores.

70 Life questionnaire - Visual Analog Score [EQ-VAS]), levels of antioxidants, use of opiates, and adver

71 changes in global, muscle, and extramuscular VAS scores (P < 0.05).

72 Fatigue VAS scores were significantly lower in the CBTH group at

73 erall significant differences were found for VAS score (warm saline group: baseline=8.9+/-0.6, 1 mont

74 le and 0.65, 0.99 and 0.12, respectively for VAS pain.

75 Testing characteristics were similar for VAS(O), AMS-C, and CFS vs a score of 5 or greater on the

76 30-mm decreases in at least two of the four VAS scores was higher in the rituximab group at week 6 (

77 kload was greater in the interruption group (VAS score, 4.22 vs 3.80; mean difference, 0.41; 95% CI,

78 al tDCS group, compared with the sham group, VAS ratings for hunger and the urge to eat declined sign

79 r = 0.788; US, r = 0.811) and global health VAS (NL, r = -0.517; US, r = -0.593) was good.

80 */G men 12 months after the disc herniation (VAS, p = 0.043, one-way ANOVA; p = 0.035, Tukey HSD).

81 th more restricted joint movement and higher VAS.

82 ients with a history of FESS reported higher VAS levels for impaired smell.

83 survival and survival with acceptable hrQoL (VAS>/=60).

84 ent and over 50% had severe work impairment (VAS-work >50).

85 The patient reported pain of 8-10 in VAS (Visual Analogue Scale) and had an ODI (Oswestry Dis

86 Change in VAS breathlessness did not differ between active treatme

87 .819) for hospital admission and a change in VAS breathlessness of -2.6 mm (-7.0 to 1.8; p=0.253) com

88 .083) for hospital admission and a change in VAS breathlessness of 2.6 mm (-1.6 to 6.8; p=0.231) comp

89 .57, P = .0032) as well as between change in VAS score and change in bowel wall enhancement in the ar

90 een subject and parent or guardian change in VAS score between baseline and follow-up (rho = 0.71; P

91 active treatments and control, but change in VAS was greater for patients in the intravenous MgSO(4)

92 103 (integrin alphaEbeta7) expressing DCs in VAS versus VAD piglets postchallenge, indicating that VA

93 urrence, there were significant decreases in VAS scores in both the dabrafenib plus trametinib group

94 There was no statistical difference in VAS for nausea, but it was numerically superior with apr

95 group at 6 months, with a mean difference in VAS score between the IPC group and the talc group of -1

96 The mean +/- SD difference in VAS was 51.6 +/- 28.11 mm in favor of the anesthetic gel

97 were no clinically meaningful differences in VAS scores or utility scores in the dabrafenib plus tram

98 tion with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nos

99 No differences were found in VAS scale between groups (SG, 36.2 +/- 24.8; nSG, 21.5 +

100 D arm experienced significant improvement in VAS pain [mean (95% CI) worst pain in the past month, fr

101 above-mentioned inflammatory measurements in VAS group and VAN group were similar in OVA-induced AD m

102 An improvement of at least 30 mm in VAS fatigue score was more common with rituximab at week

103 uce the severity of nausea when reduction in VAS score was used as the primary outcome.

104 endoscopic nasal polyp score, all individual VAS symptom scores, and Sino-Nasal Outcome Test patient-

105 nasal polyp score, improvement in individual VAS symptoms (rhinorrhea, mucus in throat, nasal blockag

106 the nonselective NAD(P)H oxidase inhibitors VAS-2870, AEBSF, and the Nox1 NAD(P)H oxidase-specific i

107 , higher EQ5D score (P = 0.016), and a lower VAS pain score (P = 0.011).

108 Mean VAS change from pre- to post-treatment did not differ si

109 Mean VAS pain scores immediately after IVT and 4 hours after

110 Mean VAS score before the procedure was 7.75 of 10.

111 oup (n = 54) vs the 24F group (n = 56) (mean VAS score, 22.0 mm vs 26.8 mm; adjusted difference, -6.0

112 difference in the first 42 days with a mean VAS dyspnea score of 24.7 in the IPC group (95% CI, 19.3

113 Smooth-bordered lesions received a mean VAS score of 1.76, corresponding to a fair response on a

114 Irregularly bordered lesions received a mean VAS score of 3.67, corresponding to an excellent respons

115 144) were not significantly different (mean VAS score, 23.8 mm vs 22.1 mm; adjusted difference, -1.5

116 rative pain was less in the SPLC-group (mean VAS 1 vs 2, p = 0.005), there were no differences in com

117 In both groups, mean VAS and EHP30 scores improved significantly and remained

118 The pre- and posttreatment mean VAS scores significantly differed (7.9 +/- 1.4 and 0.0 +

119 The mean VAS score decreased 1 month after FICS from 4.2 +/- 3.2

120 Similarly, median VAS scores for the degree to which pain interfered with

121 Results The median VAS score was 47.5 (interquartile range [IQR]: 20.0-52.2

122 n in SC patients (26 +/- 4 mm vs 39 +/- 4 mm VAS, respectively, p = 0.012) but there were no signific

123 ing the pain intensity during the 12 months (VAS, p = 0.002; McGill, p = 0.021; ODI, p = 0.205, repea

124 ng long-term follow-up (range 15-48 months), VAS and utility scores were similar between groups and d

125 ergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS

126 Nausea VAS scores correlated positively with plasma vasopressin

127 t improvement in obsessions (measured by OCD-VAS) during the infusion compared with subjects receivin

128 The OCD visual analog scale (OCD-VAS) and the Yale-Brown Obsessive-Compulsive Scale (Y-BO

129 global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as

130 P-1 and PYY secretion, suppressed aspects of VAS-rated appetite, and decreased ad libitum EI at a sub

131 A total of 1136 users filled in 5818 days of VAS-work.

132 There were no significant differences of VAS scores for perception of discomfort for periodontal

133 nts were uncontrolled based on evaluation of VAS global rhinosinusitis symptom score compared to 40.9

134 onal health and pain was a good predictor of VAS.

135 aim of this study was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK f

136 d twenty-two users filled in 112,054 days of VASs in 2016 and 2017.

137 ell as the level of disease control based on VAS global rhinosinusitis symptom score and adapted EPOS

138 ects were stratified into quartiles based on VAS nausea scores, with the upper and lower quartiles co

139 nctionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms

140 A total of 6 949 users reported at least one VAS data recording.

141 is currently in phase 2 clinical trials, or VAS-2870 attenuated NLRP3 inflammasome activation.

142 tion was observed between VAS work and other VAS.

143 rk VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained

144 VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a s

145 e likelihood of clinically significant pain (VAS rating, >/=5.4) was significantly greater with 30-ga

146 al signs (objective SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems) and previous treatm

147 CI, -33.1 to -50.2), and higher preoperative VAS preparedness (difference, 32.4; 95% CI, 24.9-39.8),

148 In addition, VR led to lower preoperative VAS stress score (difference, -41.7; 95% CI, -33.1 to -5

149 placebo) correlating with improved pruritus (VAS, P = .01) suggesting reduced biliary damage.

150 nd evening (P = .007) intensity of pruritus (VAS) and improved the validated 5D-Itch questionnaire (P

151 y end point was >=50% reduction of pruritus (VAS; intention-to-treat).

152 ctive SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems) and previous treatment of AD were

153 no significant differences between repeated VAS scores for pain perception (P = 0.91) or anxiety (P

154 a low quality of data arising from repeated VAS measures.

155 nificant correlations between child-reported VAS score and (a) the degree of bowel wall enhancement i

156 The MASK-rhinitis VAS is a reliable and valid tool to assess allergic cont

157 vity, and acceptability of the MASK-Rhinitis VAS.

158 orative stimuli using a visual analog scale (VAS) and a Schiff scale.

159 and leg pain using the visual analog scale (VAS) and opioid dose (milligrams morphine equivalent/day

160 y outcome was the EQ-5D visual analog scale (VAS) at 6 months.

161 th the TTO method and a visual analog scale (VAS) by using a questionnaire administered by means of a

162 outcome was grade in a visual analog scale (VAS) consisting of 4 levels of treatment response: poor

163 Pain assessment on the visual analog scale (VAS) during blue light illumination was not significantl

164 life questionnaire and visual analog scale (VAS) during the peak season of moderate amount of pollen

165 conjunctival staining, visual analog scale (VAS) for dry eye symptoms VAS severity, and Ocular Surfa

166 Pain was measured on a visual analog scale (VAS) from 0 to 10 before and immediately after the proce

167 leted daily 100-mm line visual analog scale (VAS) of dyspnea over 42 days after undergoing the interv

168 tient-reported 0-to-100 visual analog scale (VAS) of nausea severity.

169 ported pain rating on a visual analog scale (VAS) on either side of the face and arms and the proport

170 The median visual analog scale (VAS) pain score (scale, 0-10) decreased from 8 before tr

171 A visual analog scale (VAS) score for pain was used to assess changes in sympto

172 truments, including the visual analog scale (VAS) score, which quantifies the overall feeling of sick

173 asal polyposis severity visual analog scale (VAS) score.

174 ptions were measured by visual analog scale (VAS) scores and by interview of patients (N = 102) under

175 d through comparison of visual analog scale (VAS) scores before and 1 month after FICS.

176 uscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN ge

177 In addition, a visual analog scale (VAS) was used to evaluate the impact of KM upon brushing

178 he CRS disease severity visual analog scale (VAS), 22-item Sino-Nasal Outcome Test (SNOT-22), 5-dimen

179 /or pain according to a visual analog scale (VAS), a health-related quality of life score (Skindex-29

180 measurement based on a visual analog scale (VAS), and patient-stated preference after the second stu

181 ability were rated on a visual analog scale (VAS), by McGill Sensory Questionnaire and by Oswestry Di

182 tandard gamble (SG) and visual analog scale (VAS), in SLE patients.

183 toms of nose and eye by visual analog scale (VAS), quality of life (QOL) scores by Japanese rhino-con

184 toms of nose and eye by visual analog scale (VAS), quality of life (QOL) scores by Japanese rhino-con

185 toms of nose and eye by visual analog scale (VAS), symptom scores and combined symptom-medication sco

186 ately afterward using a visual analog scale (VAS), the 17-item Hamilton Depression Rating Scale (HDRS

187 te was evaluated with a visual analog scale (VAS).

188 as pain measured by the visual analog scale (VAS).

189 was noted according to visual analog scale (VAS).

190 was assessed by using a visual analog scale (VAS).

191 life questionnaire and visual analog scale (VAS).

192 f-reported anxiety on a visual analog scale (VAS-Anxiety).

193 in was assessed via the visual analog scale (VAS; range, 1-10) at 2 time points: (1) immediately afte

194 symptoms, measured on a visual-analog-scale (VAS), and secondary outcome was eradication of D. fragil

195 The satisfaction visual analogue scale (VAS) after using the medical device was higher than befo

196 Nasal visual analogue scale (VAS) and blockage scores were worse between baseline vs.

197 ms were assessed by a visual analogue scale (VAS) and symptom specific quality of life questionnaire

198 outcome measures were visual analogue scale (VAS) assessments for "pain," "numbness," and "groin disc

199 ui torticollis scale, Visual Analogue Scale (VAS) for pain and Fugl-Meyer scale for QoL.

200 Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome.

201 measured on a 100 mm visual analogue scale (VAS) in the 2 h after initiation of treatment.

202 Visual Analogue Scale (VAS) is a validated tool to assess control in allergic r

203 scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume.

204 reported pain using a visual analogue scale (VAS) recorded on the 0 to 100 scale at 7 and 14 days, an

205 ect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal

206 Weekly visual analogue scale (VAS) scores for myalgia and specific symptoms (VAS myalg

207 POS control criteria, visual analogue scale (VAS) scores for total and individual sinonasal symptoms,

208 IS were scored with a visual analogue scale (VAS) to assess overall severity.

209 questionnaires and a visual analogue scale (VAS) were used for the assessment of anxiety and nausea.

210 ted pleasantness on a visual analogue scale (VAS) when we stroked with a soft brush with speeds from

211 f eye dryness using a visual analogue scale (VAS), and noninvasive tear film breakup time (NITBUT).

212 rotein (hs-CRP) and a visual analogue scale (VAS), respectively.

213 Qol questionnaire and visual analogue scale (VAS).

214 i) to follow-up using visual analogue scale (VAS).

215 rhinitis assessed by visual analogue scale (VAS).

216 d-type Elstar using a visual analogue scale (VAS).

217 IA severity items and visual analogue scale (VAS).

218 03 in EQ-5D-3L visual analogue rating scale (VAS) scores, with mean change from baseline to week 103

219 in place (0- to 100-mm visual analog scale [VAS] 4 times/d; superiority comparison) and pleurodesis

220 n of the back and legs (Visual Analog Scale [VAS] pain score >=60 mm; Oswestry Disability Index [ODI]

221 an metoclopramide (mean visual analog scale [VAS] score, 4.1 [SD, 2.9] for ondansetron vs 5.7 [SD, 2.

222 pruritus (>=5 of 10 on visual analog scale [VAS]) due to PSC, PBC, or SSC were recruited for this do

223 n (>/=50 mm on a 100 mm visual analog scale [VAS]) received 375 mg NTG 0.4% (1.5 mg active ingredient

224 ) and the EQ-5D (with a visual analog scale [VAS])-were completed at baseline, 30 days, 6 months, and

225 workload (on a 10-point visual analog scale [VAS]).

226 ent of HRQOL utilities (visual analog scale [VAS], time trade-off [TTO], and standard gamble [SG]), M

227 ain (measured using a visual analogue scale [VAS]) and length of ICU stay.

228 e was pain intensity (Visual analogue scale [VAS]) and physical function (Western Ontario and McMaste

229 re (EDS) >/=40 (0-100 visual analogue scale [VAS]), and history of artificial tear use within 30 days

230 ing were measured with visual analog scales (VAS) and a Drug Effects Questionnaire.

231 aded 100-mm horizontal visual analog scales (VAS) representing right and left sides of the mouth.

232 ing, and cooling using visual analog scales (VAS).

233 fe Questionnaire and visual analogue scales (VAS) for dysmenorrhea, chronic pelvic pain, and deep dys

234 alth Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal complaints, pain and tiredness

235 ects data from daily visual analogue scales (VAS) for overall allergic symptoms (VAS-global measured)

236 pants completed four Visual Analogue Scales (VAS) to assess musical sound quality.

237 S) assessed by daily visual analogue scales (VAS).

238 sessed with the use of visual analog scales (VASs), blood samples collected, and ad libitum energy in

239 -Fatigue subscale and Visual Analog Scales (VASs; Fatigue and Muscle Weakness).

240 tomous questions and visual analogue scales (VASs) were used to assess self-reported pain, willingnes

241 ns were monitored using visual analog score (VAS) 12 weeks after onset of fever in 130 patients.

242 >/=8 years completed a visual analog score (VAS) for pain.

243 res were SF-36 score, Visual Analogue Score (VAS) pain score, EuroQol-5D-3L (EQ-5D-3L) score, morbidi

244 OOS) and knee pain by visual analogue score (VAS).

245 4 scale) in study eye, eye discomfort score (VAS), total corneal staining score in the study eye, and

246 om baseline to day 84, in eye dryness score (VAS, both eyes) and inferior corneal fluorescein stainin

247 el was 23.5 +/- 16.8 mm, and the mean +/- SD VAS for the placebo gel was 23.5 +/- 14.6 mm.

248 The mean +/- SD VAS for the test gel was 23.5 +/- 16.8 mm, and the mean

249 ore painful with 30-gauge needles (mean [SD] VAS ratings for the face, 4.16 [2.55] vs 3.41 [2.31], P

250 The mean+/-standard error of the mean (SEM) VAS pain scores immediately after intravitreal injection

251 rying cognate variable activating sequences (VAS) in distinct neighbouring cell types of the Drosophi

252 cant improvement in nasal polyposis severity VAS score, endoscopic nasal polyp score, all individual

253 included change in nasal polyposis severity VAS score, endoscopic nasal polyp score, improvement in

254 essed and nonvocoded virtual acoustic space (VAS) stimuli.

255 We used virtual auditory space (VAS) methods for sounds at various distances in anechoic

256 o in the VAS myalgia score, symptom-specific VAS score, pain interference score, and pain severity sc

257 toms (VAS myalgia score and symptom-specific VAS score, respectively), pain interference scores, and

258 ension EuroQoL (EQ-5D) general health status VAS, and 36-item Short-Form Health Survey (SF-36) for HR

259 The VAD and vitamin A-sufficient (VAS) Gn pigs were vaccinated with attenuated HRV (AttHRV

260 model on VAD and vitamin A supplementation (VAS) model in wild-type mice (C57BL/6) and established A

261 It supports VAS for symptom assessment and placebo-based analysis as

262 sual analog scale (VAS) for dry eye symptoms VAS severity, and Ocular Surface Disease Index (OSDI) qu

263 scales (VAS) for overall allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocu

264 l), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as work (VAS-work).

265 S) scores for myalgia and specific symptoms (VAS myalgia score and symptom-specific VAS score, respec

266 Since the number of combinatorial TALE-VAS pairs is virtually unlimited, this platform provides

267 The VAS pain scores showed favorable anesthetic efficacy of

268 sm and NITBUT (P = 0.013, d = 1.08); and the VAS and DEQ-5 (P = 0.034, d = 0.58).

269 Both the EQ-5D index and the VAS score declined in a stepwise fashion with increasing

270 .6 [95% CI, 7.9 to 51.2] [P = .009]) and the VAS score for pruritus (MD, 4.6 [95% CI, 1.5 to 7.7] [P

271 ensitivity when users (n = 521) answered the VAS twice in less than 3 hours.

272 All consecutive users who completed the VAS-work from 1 June to 31 October 2016 were included in

273 cially the distribution of responses for the VAS.

274 Serelaxin improved the VAS AUC primary dyspnoea endpoint (448 mm x h, 95% CI 12

275 were seen between statin and placebo in the VAS myalgia score, symptom-specific VAS score, pain inte

276 rimary outcome measure (46% reduction in the VAS score in the aprepitant group vs 40% reduction in th

277 x Treatment: F9,115=2.6, p=0.01) but not the VAS-Anxiety (Time x Treatment: F10,141=0.4, p=0.95).

278 with fish oil resulted in about half of the VAS pain reduction of the other 2 arms.

279 ticipants who self-reported more pain on the VAS scale produced higher levels of IL6 compared with th

280 ity in evaluation of overall severity on the VAS when assessing the endoscopic severity of UC and was

281 stic subgroups for our primary outcomes, the VAS and the HDRS-17.

282 After UV-A1 phototherapy, the VAS score for burning and/or pain (MD, 3.2 [95% CI, 0.7

283 These findings suggested that the VAS and EQ-5D might be valid and reliable measures to as

284 The primary outcome was the VAS myalgia score (range, 0 to 100 mm).

285 Therapeutic VAS can rescue VAD-aggravated eAD.

286 l study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer quest

287 levels of control corresponded to mean total VAS, SNOT-22 and SF-36 scores.

288 Patients' interaction (measured using VAS) was improved with dexmedetomidine (estimated score

289 ha levels were induced in control VAD versus VAS piglet sera at postchallenge day 2.

290 Muscle Weakness VAS scores were significantly lower in the CBTH group at

291 nd arms and the proportion of patients whose VAS ratings corresponded with more than moderate (ie, cl

292 Esthetics outcome was assessed with VAS and the Questionnaire of Oral Esthetic Satisfaction.

293 substantially postchallenge as compared with VAS pigs.

294 In comparison with VAS global, the mCSMS and MASK control score showed a lo

295 The highest levels for correlation with VAS work and variance explained in VAS work were found w

296 ontrol score showed a lower correlation with VAS work.

297 riance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma.

298 No association was identified with VAS stress score (difference, -1.6; 95% CI, -13.4 to 10.

299 aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measuremen

300 sthma symptoms (VAS-asthma) as well as work (VAS-work).